Novel Ophthalmic Topical Formulation Targeting Molecular Pathogenesis Of Corneal Haze
Funder
National Health and Medical Research Council
Funding Amount
$296,090.00
Summary
Presently, no drugs are proven to cure corneal haze/scarring, major leading cause of global blindness. Haze is caused by eye trauma, infections or refractive laser surgeries. We aim to test a non toxic, novel ophthalmic topical formulation developed to act on molecular and cellular targets of haze formation. The successful completion of the study will determine formulation’s optimal dose, safety and efficacy for its future potential clinical use in reversing corneal scarring/haze without side ef ....Presently, no drugs are proven to cure corneal haze/scarring, major leading cause of global blindness. Haze is caused by eye trauma, infections or refractive laser surgeries. We aim to test a non toxic, novel ophthalmic topical formulation developed to act on molecular and cellular targets of haze formation. The successful completion of the study will determine formulation’s optimal dose, safety and efficacy for its future potential clinical use in reversing corneal scarring/haze without side effects.Read moreRead less
Toxoplasma Gondii Infection Of Human Retinal Pigment Epithelium
Funder
National Health and Medical Research Council
Funding Amount
$460,668.00
Summary
Ocular toxoplasmosis is a vision-threatening parasitic eye infection that is common in Australia and worldwide. No treatment cures the disease. This work will characterize cellular and molecular events occuring in the eye during an infection, which is an important first step toward the development of more effective treatments for patients with the condition.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Young Adult Myopia: Genetic And Environmental Associations
Funder
National Health and Medical Research Council
Funding Amount
$809,271.00
Summary
Myopia affects 80% of school leavers in the cities of East Asia, 45% of Asian Australian school leavers and is probably on the rise in European Australian adolescents. Increased levels of education and lack of time outdoors are known to increase the risk of myopia. We will examine 2,000 young adults to find the genes that interact with these risk factors. In addition to confirming when these risk factors are most important, identifying molecular pathways opens the avenue of new treatments.